search
Back to results

The Correlation of Surgical Colorectal Cancer Specimen Pathology With the Fluorescence of Photodynamic Diagnostics (PDD)

Primary Purpose

Colorectal Cancer, Photodynamic Diagnosis

Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Cysview
Sponsored by
Dr. Te Vuong
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Colorectal Cancer focused on measuring Fluorescence Sigmoidoscopy, PDD, Photodynamic Diagnosis

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients older than 18 years of age with diagnosed colorectal cancer.
  • Colorectal cancer patients treated with Chemotherapy and external beam radiation therapy

Exclusion Criteria:

  • 1) Liver cirrhosis
  • 2) Acute or chronic hepatitis
  • 3) Elevated liver function tests of unknown etiology with elevation of transaminases of more than 3 times normal levels
  • 4) Known porphyria
  • 5) Pregnancy
  • 6) Expected lack of compliance

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Blue Light Cystoscopy with Cysview®

    Arm Description

    The enema will be administered to participant. Fluorescence sigmoidoscopy will be performed with white light then blue excitation light after retention of the enema for 60 minutes, followed by a rest time of up to 30 minutes before rectoscopy. Post-operative surgical specimens will be collected for further fluorescence microscopy studies and pathological correlation of fluoresce with malignant pathology/histology as the gold standard.

    Outcomes

    Primary Outcome Measures

    fluorescence with photodynamic diagnostics (PDD) in colorectal cancer
    To observe red fluorescence wirh PDD when lesions are illuminate with blue fluorescence during fluorescence sigmoidoscopy.

    Secondary Outcome Measures

    Detect malignant lesions
    Using the images of fluorescence sigmoidoscopy, detect malignant lesions after neoadjuvant chemotherapy and radiation.

    Full Information

    First Posted
    August 30, 2017
    Last Updated
    September 17, 2019
    Sponsor
    Dr. Te Vuong
    Collaborators
    KARL STORZ Endoscopy-America, Inc.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03272659
    Brief Title
    The Correlation of Surgical Colorectal Cancer Specimen Pathology With the Fluorescence of Photodynamic Diagnostics
    Acronym
    PDD
    Official Title
    The Correlation of Surgical Colorectal Cancer Specimen Pathology With the Fluorescence of Photodynamic Diagnostics (PDD): a Clinical Pilot Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2019
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Long process and due to strict deadline, project was stopped.
    Study Start Date
    April 1, 2018 (Anticipated)
    Primary Completion Date
    December 1, 2018 (Anticipated)
    Study Completion Date
    April 1, 2019 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    Dr. Te Vuong
    Collaborators
    KARL STORZ Endoscopy-America, Inc.

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    This will be a pilot study involving 5 patients diagnosed with colorectal carcinoma and treated with pre-operative chemotherapy and external beam radiation therapy at the Jewish General Hospital, whom will very soon undergo surgery. Participants will be sensitized by the instillation of a 250 mL enema containing 1.6 mmol of HAL. The enema will be administered with a plastic tube with an inflatable blocking balloon to prevent leakage of the enema. Fluorescence sigmoidoscopy will be performed with white light then blue excitation light after retention of the enema for 60 minutes, followed by a rest time of up to 30 minutes before rectoscopy. Red fluorescence should be induced by illumination with blue light. Pictures with and without fluorescence will be taken. The patients will undergo a colectomy (partial or complete) within the next 2-3 days and the surgical specimens will be collected for further fluorescence microscopy studies and pathological correlation of fluoresce with malignant pathology/histology as the gold standard. The total concentration of porphyrins in the patients' urine and serum will be recorded before sensitization, immediately after sensitization (instillation of the enema), and approximately 24 hours after sensitization. The patients' pre-and-post operative liver function tests will be measured. Adverse events will be reported by direct questioning of all patients with regards to photosensitivity and gastrointestinal symptoms (nausea, vomiting), and by measuring blood pressure and heart rate. Our objectives and endpoints are: 1) to determine if fluorescence with photodynamic diagnostics is selective for colorectal cancer, 2) to determine if photodynamic diagnostics has the potential to improve the detection of malignant cell after neoadjuvant chemotherapy and radiation, and 3) to determine if photodynamic diagnostics can provide an accurate depiction of the extent of disease burden not visible with normal white light sigmoidoscopy to the naked human eye.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Colorectal Cancer, Photodynamic Diagnosis
    Keywords
    Fluorescence Sigmoidoscopy, PDD, Photodynamic Diagnosis

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Phase 2
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Blue Light Cystoscopy with Cysview®
    Arm Type
    Experimental
    Arm Description
    The enema will be administered to participant. Fluorescence sigmoidoscopy will be performed with white light then blue excitation light after retention of the enema for 60 minutes, followed by a rest time of up to 30 minutes before rectoscopy. Post-operative surgical specimens will be collected for further fluorescence microscopy studies and pathological correlation of fluoresce with malignant pathology/histology as the gold standard.
    Intervention Type
    Drug
    Intervention Name(s)
    Cysview
    Other Intervention Name(s)
    hexaminolevulinate
    Intervention Description
    250 mL enema containing 1.6 mmol of hexaminolevulinate
    Primary Outcome Measure Information:
    Title
    fluorescence with photodynamic diagnostics (PDD) in colorectal cancer
    Description
    To observe red fluorescence wirh PDD when lesions are illuminate with blue fluorescence during fluorescence sigmoidoscopy.
    Time Frame
    9 months
    Secondary Outcome Measure Information:
    Title
    Detect malignant lesions
    Description
    Using the images of fluorescence sigmoidoscopy, detect malignant lesions after neoadjuvant chemotherapy and radiation.
    Time Frame
    9 months
    Other Pre-specified Outcome Measures:
    Title
    Accurate depiction of the extent of disease burden by correlating pre-and post surgical results after neoadjuvant chemotherapy and radiation.
    Time Frame
    9 months

    10. Eligibility

    Sex
    All
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients older than 18 years of age with diagnosed colorectal cancer. Colorectal cancer patients treated with Chemotherapy and external beam radiation therapy Exclusion Criteria: 1) Liver cirrhosis 2) Acute or chronic hepatitis 3) Elevated liver function tests of unknown etiology with elevation of transaminases of more than 3 times normal levels 4) Known porphyria 5) Pregnancy 6) Expected lack of compliance

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    15332045
    Citation
    Endlicher E, Gelbmann CM, Knuchel R, Furst A, Szeimies RM, Golder SK, Scholmerich J, Lottner C, Messmann H. Hexaminolevulinate-induced fluorescence endoscopy in patients with rectal adenoma and cancer: a pilot study. Gastrointest Endosc. 2004 Sep;60(3):449-54. doi: 10.1016/s0016-5107(04)01723-7.
    Results Reference
    background
    PubMed Identifier
    18197583
    Citation
    Mayinger B, Neumann F, Kastner C, Degitz K, Hahn EG, Schwab D. Early detection of premalignant conditions in the colon by fluorescence endoscopy using local sensitization with hexaminolevulinate. Endoscopy. 2008 Feb;40(2):106-9. doi: 10.1055/s-2007-967019. Epub 2008 Jan 16.
    Results Reference
    background
    PubMed Identifier
    20066590
    Citation
    Mayinger B, Neumann F, Kastner C, Haider T, Schwab D. Hexaminolevulinate-induced fluorescence colonoscopy versus white light endoscopy for diagnosis of neoplastic lesions in the colon. Endoscopy. 2010 Jan;42(1):28-33. doi: 10.1055/s-0029-1243804. Epub 2010 Jan 11.
    Results Reference
    background
    PubMed Identifier
    28324275
    Citation
    Pietzak EJ. The Impact of Blue Light Cystoscopy on the Diagnosis and Treatment of Bladder Cancer. Curr Urol Rep. 2017 May;18(5):39. doi: 10.1007/s11934-017-0685-8.
    Results Reference
    background
    PubMed Identifier
    25651787
    Citation
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.
    Results Reference
    background

    Learn more about this trial

    The Correlation of Surgical Colorectal Cancer Specimen Pathology With the Fluorescence of Photodynamic Diagnostics

    We'll reach out to this number within 24 hrs